This is a Phase 1/2, multi-center, randomized, sham-controlled, dose-escalation study evaluating ZM-02 in patients with advanced retinitis pigmentosa (RP).
Male or female participants aged 6 to 60 years.
Clinical diagnosis of advanced retinitis pigmentosa (RP).
Best corrected visual acuity at or below the protocol-defined threshold in the study eye.
Presence of sufficient retinal structure in the study eye as determined by screening assessments.
Presence of other ocular conditions that could interfere with study assessments.
History of significant ocular surgery in the study eye within a protocol-defined period.
Active ocular infection or inflammation.
Clinically significant systemic disease that could increase study risk or interfere with assessments.